No human trial has directly compared senolytic cycling frequencies. Based on senescent cell reaccumulation kinetics in animals (50% recovery within 4–8 weeks) and clinical trial designs, monthly cycling is preferred for individuals 55+ or with high inflammatory burden; quarterly is appropriate for prevention in those under 50.
What happens if I miss a cycle?
Senescent cells continue to accumulate during missed cycles, but the long-term impact of occasional missed cycles is modest. Resume on your regular schedule without doubling doses.
Should I take a break from senolytic cycling?
No evidence supports "senolytic holidays." Unlike some drugs that develop resistance, senescent cells remain sensitive to senolytic treatment regardless of prior cycling history.
Can I combine monthly fisetin with quarterly dasatinib?
Yes. This "layered" approach provides monthly natural senolytic maintenance plus quarterly pharmaceutical senolytic boost. The fisetin cycles and dasatinib cycles can overlap (fisetin on dasatinib days) or be alternated.
Monthly or quarterly cycling schedules are hypotheses, not validated recommendations for healthy people. A pulse schedule does not remove the need for dose-specific safety evidence or interaction review. Do not copy animal protocols or trial regimens; the study's medical supervision and eligibility criteria are part of how those data were obtained.
Senescence research distinguishes cell and animal mechanisms from demonstrated human health outcomes. A change in a marker does not prove that senescent cells were cleared or that symptoms, disease risk, or lifespan changed. No self-directed preventive dose or schedule is established. Do not use prescription drugs or high-dose supplements as an online protocol; discuss relevant symptoms and treatments with a clinician.